Physician profile

James Kelly

Kankakee, IL

NPI 1881679553

$6,144.97

in general payments reported to CMS, 2019-2025

29 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Abbott Laboratories $2,787.42 2019-2021
Collegium Pharmaceutical, INC. $454.74 2019-2021
Daiichi Sankyo INC. $411.85 2019
Arbor Pharmaceuticals, INC. $322.69 2019-2021
Teva Pharmaceuticals USA, INC. $279.06 2020-2021
Pfizer INC. $251.03 2019-2021
Novartis Pharmaceuticals Corporation $232.82 2019-2021
Lilly USA, LLC $198.46 2019-2021
Amgen INC. $182.54 2019-2021
Abbvie INC. $156.82 2021
Takeda Pharmaceuticals U.S.A., INC. $152.55 2019
Sentynl Therapeutics, INC. $107.53 2019
Boston Scientific Corporation $106.47 2021
Redhill Biopharma INC. $54.83 2020-2021
Allergan, INC. $52.67 2020-2021
Show all 29 companies

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

James Kelly

$6,144.97

in general payments reported 2019-2025

Years
2019-2021
Top company
Abbott Laboratories

https://glasscript.com/doctor/312021/james-kelly

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.